Physician profile
William E Webb
NPI 1699797324
$3,473.22
in general payments reported to CMS, 2019-2025
21 companies · $16.00 in 2025
The $16.00 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $146 · 2021: $617 · 2022: $926 · 2023: $1,076 · 2024: $462 · 2025: $16.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,123.04 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $460.48 | 2021-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $387.39 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $363.59 | 2021-2024 | Dyanavel Xr |
| Sanofi Pasteur INC. | $190.88 | 2019-2024 | |
| Pfizer INC. | $153.09 | 2019-2025 | |
| Sobi, INC | $114.75 | 2021-2024 | |
| Adlon Therapeutics L.P. | $114.55 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.33 | 2021-2023 | Lifevest |
| Glaxosmithkline, LLC. | $97.39 | 2020-2024 | Rotarix, Bexsero |
| Merck Sharp & Dohme LLC | $80.12 | 2019-2024 | Gardasil 9, Gardasil, M-M-R II |
| Takeda Pharmaceuticals U.S.A., INC. | $62.44 | 2019-2020 | |
| Genentech USA, INC. | $56.88 | 2019-2021 | |
| Seqirus USA INC | $40.57 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Phadia US INC. | $23.45 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $22.66 | 2023 | |
| Ironwood Pharmaceuticals, INC | $22.05 | 2024 | |
| Kaleo, INC. | $19.20 | 2019 | |
| Neos Therapeutics, Lp | $13.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.37 | 2021 | |
| Shire North American Group INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.